Zacks Investment Research on MSN15h
Exelixis Stock Rises 13.3% Year to Date: Buy, Sell or Hold?
Shares of Exelixis, Inc. EXEL have risen 13.3% year to date compared with the industry’s growth of 6.6%. The stock has also ...
Summit Therapeutics rises as lead asset makes Citi its latest bull
Summit Therapeutics (NASDAQ:SMMT) traded higher in the premarket on Wednesday after Citi upgraded the stock to Buy from ...
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be ...